BRPI0407249A - Preparação de quinazolinas substituìdas - Google Patents

Preparação de quinazolinas substituìdas

Info

Publication number
BRPI0407249A
BRPI0407249A BR0407249-9A BRPI0407249A BRPI0407249A BR PI0407249 A BRPI0407249 A BR PI0407249A BR PI0407249 A BRPI0407249 A BR PI0407249A BR PI0407249 A BRPI0407249 A BR PI0407249A
Authority
BR
Brazil
Prior art keywords
preparation
inhibitors
substituted quinazolines
diacryloylamino
quinazolins
Prior art date
Application number
BR0407249-9A
Other languages
English (en)
Inventor
Hubert Gangolf Klemens Barth
Alexander James Bridges
Ronald Joseph Heemstra
Nicole Marcia Horne
Robert Craig Hughes
Thomas Elliott Jacks
Dennis Joseph Mcnamara
Simon Schneider
Klaus Irenous Steiner
Peter Laurence Toogood
Roy Thomas Winters
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0407249A publication Critical patent/BRPI0407249A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"PREPARAçãO DE QUINAZOLINAS SUBSTITUìDAS". A presente invenção refere-se a métodos e materiais para preparar inibidores irreversíveis de tirosina-cinases de Fórmula geral (1). Estes inibidores, os quais incluem N-¢4-(3-cloro-4-flúor-fenilamino)-7-(3-morfolin-4-il-propóxi)-quinazolin- 6-il!-acrilamida, são úteis para tratar o câncer, restenose, aterosclerose, endometriose e psoríase. Os métodos descritos utilizam esquemas de proteção para minimizar produtos secundários indesejáveis de diacriloilamino-quinazolina.
BR0407249-9A 2003-02-05 2004-02-03 Preparação de quinazolinas substituìdas BRPI0407249A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44509503P 2003-02-05 2003-02-05
PCT/IB2004/000321 WO2004069791A2 (en) 2003-02-05 2004-02-03 Preparation of substituted quinazolines

Publications (1)

Publication Number Publication Date
BRPI0407249A true BRPI0407249A (pt) 2006-01-31

Family

ID=32850969

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0407249-9A BRPI0407249A (pt) 2003-02-05 2004-02-03 Preparação de quinazolinas substituìdas

Country Status (18)

Country Link
US (1) US20040158065A1 (pt)
EP (1) EP1618095A2 (pt)
JP (1) JP2006517959A (pt)
KR (1) KR20050095916A (pt)
CN (1) CN1745073A (pt)
AR (1) AR043027A1 (pt)
AU (1) AU2004209452A1 (pt)
BR (1) BRPI0407249A (pt)
CA (1) CA2514933A1 (pt)
MX (1) MXPA05007831A (pt)
NL (3) NL1025414C2 (pt)
PA (1) PA8595201A1 (pt)
PE (1) PE20040945A1 (pt)
PL (1) PL378576A1 (pt)
RU (1) RU2005122322A (pt)
TW (1) TW200420544A (pt)
UY (1) UY28177A1 (pt)
WO (1) WO2004069791A2 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU90901A (sh) 1999-06-21 2004-07-15 Boehringer Ingelheim Pharma Gmbh. & Co.Kg. Biciklični heterocikli, lekovi koji sadrže ta jedinjenja, njihova primena i postupci za njihovo pripremanje
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
JP4828421B2 (ja) * 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
DE10349113A1 (de) * 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
AP2204A (en) * 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
KR100735639B1 (ko) * 2004-12-29 2007-07-04 한미약품 주식회사 암세포 성장 억제 효과를 갖는 퀴나졸린 유도체 및 이의제조방법
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
CA2755268C (en) * 2005-11-15 2013-12-31 Array Biopharma, Inc. Erbb inhibitors
BRPI0717586A2 (pt) * 2006-09-18 2013-10-29 Boehringer Ingelheim Int Método para tratar câncer apresentando mutações do egfr
JP5474792B2 (ja) * 2007-09-10 2014-04-16 キュリス，インコーポレイテッド 亜鉛結合部分を含むキナゾリンベースｅｇｆｒインヒビターの酒石酸塩またはその複合体
US8609673B2 (en) * 2008-01-22 2013-12-17 Concert Pharmaceuticals, Inc. Vandetanib derivatives
WO2009094216A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Derivatives of gefitinib
KR101341876B1 (ko) * 2008-09-05 2013-12-20 셀진 아빌로믹스 리서치, 인코포레이티드 비가역 인히비터 디자인을 위한 알고리즘
PL2451445T3 (pl) 2009-07-06 2019-09-30 Boehringer Ingelheim International Gmbh Sposób suszenia BIBW2992, jego soli i stałych preparatów farmaceutycznych zawierających tę substancję czynną
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
AU2010339456A1 (en) 2009-12-30 2012-07-05 Celgene Avilomics Research, Inc. Ligand-directed covalent modification of protein
CN102382106A (zh) 2010-08-30 2012-03-21 黄振华 苯胺取代的喹唑啉衍生物
CN102898386B (zh) * 2011-07-27 2015-07-29 上海医药集团股份有限公司 喹唑啉衍生物、其制备方法、中间体、组合物及其应用
CN103874696B (zh) 2011-10-12 2015-06-03 苏州韬略生物科技有限公司 作为激酶抑制剂的喹唑啉衍生物及其使用方法
EP2847186B1 (en) 2012-05-07 2017-08-09 Teligene Ltd. Substituted aminoquinazolines useful as kinases inhibitors
CN103965120B (zh) * 2013-01-25 2016-08-17 上海医药集团股份有限公司 喹啉及喹唑啉衍生物、制备方法、中间体、组合物及应用
CN103242244B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 一种卡奈替尼的制备方法
EP2999702A4 (en) 2013-05-21 2017-01-11 Jiangsu Medolution Ltd. Substituted pyrazolopyrimidines as kinases inhibitors
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
KR102355955B1 (ko) * 2016-09-23 2022-01-25 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 퀴나졸린 유도체의 염, 이의 제조 방법 및 응용
MD3762368T2 (ro) 2018-03-08 2022-07-31 Incyte Corp Compuși diol aminopirazină ca inhibitori ai PI3K-Y
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
KR20210137422A (ko) 2018-09-25 2021-11-17 블랙 다이아몬드 테라퓨틱스, 인코포레이티드 티로신 키나아제 억제제로서의 퀴나졸린 유도체, 조성물, 이들의 제조 방법 및 이들의 용도
MX2021010669A (es) * 2019-03-07 2021-09-28 BioNTech SE Proceso para la preparacion de una imidazoquinolina sustituida.
CN119390683A (zh) 2019-08-15 2025-02-07 黑钻治疗公司 炔基喹唑啉化合物
US20240246940A1 (en) * 2021-04-22 2024-07-25 Voronoi Inc. Heteroaryl derivative compound and use thereof
WO2023044364A1 (en) 2021-09-15 2023-03-23 Enko Chem, Inc. Protoporphyrinogen oxidase inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3370340B2 (ja) * 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
US6664390B2 (en) * 2000-02-02 2003-12-16 Warner-Lambert Company Llc Method for the simplified production of (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazoline-4-yl]-amine or (3-chloro-4-fluorophenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazoline-4-yl]-amine
DE10009267A1 (de) * 2000-02-26 2001-08-30 Goedecke Ag Verfahren zur einfachen Herstellung von (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-nitro-quinazolin-4-yl]-amin bzw. (3-Chlor-4-fluor-phenyl)-[7-(3-morpholin-4-yl-propoxy)-6-amino-quinazolin-4-yl]-amin
US6627634B2 (en) * 2000-04-08 2003-09-30 Boehringer Ingelheim Pharma Kg Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them
DE10063435A1 (de) * 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
US20040158065A1 (en) 2004-08-12
JP2006517959A (ja) 2006-08-03
WO2004069791A2 (en) 2004-08-19
CA2514933A1 (en) 2004-08-19
TW200420544A (en) 2004-10-16
KR20050095916A (ko) 2005-10-04
NL1029763A1 (nl) 2005-10-13
NL1029763C2 (nl) 2006-03-06
NL1025414A1 (nl) 2004-08-06
UY28177A1 (es) 2004-09-30
AU2004209452A1 (en) 2004-08-19
PA8595201A1 (es) 2004-09-16
NL1025414C2 (nl) 2005-11-01
WO2004069791A3 (en) 2004-12-16
NL1029762A1 (nl) 2005-10-13
CN1745073A (zh) 2006-03-08
RU2005122322A (ru) 2006-03-10
AR043027A1 (es) 2005-07-13
PL378576A1 (pl) 2006-05-02
MXPA05007831A (es) 2005-10-18
PE20040945A1 (es) 2004-12-14
NL1029762C2 (nl) 2006-03-06
EP1618095A2 (en) 2006-01-25

Similar Documents

Publication Publication Date Title
MXPA05007831A (es) Preparacion de quinazolinas substituidas.
BRPI0412894A (pt) tienopiridina e furopiridina inibidores de quinases
AR023706A1 (es) N-[4-(3-cloro-4-fluoro-fenilamino)-7-(3-morfolin-4-il-propoxi)-quinazolin-6-il]-acrilamida, composiciones farmaceuticas que lo comprenden y uso comoinhibidor de cinasa de tirosina
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CY1106405T1 (el) Παραγωγα κουιναζολινης
WO2003050108A8 (en) Salt forms of e-2-methoxy-n-(3-(4-(3-methyl-pyridin-3-yloxy)-phenylamino)-quinazolin-6-yl)-allyl)-acetamide, its preparation and its use against cancer
CA2632556A1 (en) Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
ATE353888T1 (de) Chinazolinderivate
BR0206943A (pt) Inibidores de fosfodiesterase 4
SG149817A1 (en) Quinoline intermediates of receptor tyrosine kinase inhibitors and the synthesis thereof
TW200519096A (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
UA89038C2 (en) Pyrrolotriazine compounds as kinase inhibitors
YU84603A (sh) Novi inhibitori tirozin kinaze
BRPI0414486A (pt) derivado de quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
NO20060415L (no) Piperidyl-Kinazolinderivater som Tyrosin-Kinase-Inhibitorer
Lin et al. Novel oxazolo [4, 5-g] quinazolin-2 (1H)-ones: dual inhibitors of EGFR and Src protein tyrosine kinases
ATE240328T1 (de) Substituierte azaoxindolederivate
NO20061415L (no) Kinazolinderivater
DE60235396D1 (de) 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
BRPI0506676A (pt) piridazinona uréias como antagonistas de integrinas alfa4
BRPI0407841A (pt) inibidores heterocìclicos de quinase
BR9912575A (pt) Processo para a preparação de um composto, e, composto.
TW200514782A (en) 5-substituted quinazolinone derivatives
WO2010076764A1 (en) Irreversible egfr inhibitor compounds with antiproliferative activity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.